Tumours
Tumours

Lung

Description

EORTC has a strong track record in initiating and conducting clinical trials across thoracic cancers. The focus is not only lung cancer but also mesothelioma and thymomas. This follows EORTC strategy to challenge, re-define and develop standards of care for loco-regional as well as for systemic treatments.
Scientific projects are designed and conducted to integrate disciplines such as imaging, translational research, quality of life and quality assurance. There are multiple partnerships, especially with national groups in Europe but also with international umbrella organisations. The group places special emphasis on recruiting and mentoring junior colleagues who are interested in pursuing an academic career in the field of thoracic oncology.
Projects testing the place of immunotherapy in the treatment of lung cancer are also ongoing such as addressing the role of immunotherapy in the adjuvant setting of lung cancer.

Main Achievements

EORTC has contributed to changing the standards of care for thoracic oncology:

Established radiotherapy as the preferred loco-regional treatment in non-small-cell lung cancer patients. (More information & More information)

Demonstrated the benefit of prophylactic cranial irradiation to reduce the incidence of symptomatic brain metastases in extensive small-cell lung cancer. More information

Confirmed a combination of Cisplatin and Raltitrexed was more effective than Cisplatin alone in improving the survival of patients with Malignant Pleural Mesothelioma (MPM). More information

Related Projects

  • 1459: Exploratory analysis of the pleural mesothelioma genome by next generation sequencing
  • 1495: Update of OS in 08092 and CRP marker
  • 1496: Survey on Thymoma / thymic malignancy
  • 1492 CANCER-ID: Cancer treatment and monitoring through identification of circulating tumor cells and tumor related nucleic acids in plasma
  • 1549: Pharmacogenetic analysis from the double blind randomized phase III study ofmaintenance pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung Group study
  • 1557 Predict therapy in NSCLC: Studying changes in the expression of genes related to the metabolism and the chemotherapeutic activity in primary tumor and lymph and mediastinal lymph nodes infiltrated in resectable NSCLC
  • 1638: Phase II, Parallel-Arm Study of MGCD265 in patients with locally advanced or metastatic NSCLC with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Research Group

Group documents
  • Chair

    Benjamin Besse

    Gustave Roussy Cancer Campus

    Villejuif, France

  • Secretary

    Silvia Novello

    Ospedale S. Luigi Gonzaga - Universita Di Torino

    Orbassano, Italy

  • Treasurer

    Thierry Berghmans

    Institut Jules Bordet

    Brussels, Belgium

Other members

  • C. Faivre-Finn - Manchester, GB

    Early stage NSCLC & Radiotherapy

    The Christie NHS Foundation Trust

  • M. De Waele - Edegem, BE

    Early stage NSCLC & Surgery

    Universitair Ziekenhuis Antwerpen

  • M. Reck - Grosshansdorf, DE

    Metastatic NSCLC

    Hospital Grosshansdorf

  • L. Greillier - Marseille, FR

    Malignant Pleural Mesothelioma

    Assistance Publique - Hopitaux de Marseille - Hopital Nord

  • S. Lantuejoul - Grenoble, FR

    Pathology & TR

    CHU de Grenoble - Departement d'Anatomie et Cytologie Pathologiques

  • A. Dingemans - Maastricht, NL

    SCLC

    Academisch Ziekenhuis Maastricht

  • N. Girard - Lyon, FR

    Thymic malignancies

    CHU de Lyon - Hopital Louis Pradel

Committee(s)Close Committee(s)